PURPOSE: CCAAT/enhancer binding protein alpha (C/EBP alpha) is a transcription factor and a tumor suppressor. We aimed to assess its protein expression and prognostic value in human hepatocellular carcinoma (HCC). METHODS: We conducted a retrospective cohort study on 50 HCC patients and performed immunohistochemistry against C/EBP alpha on tumors and adjacent nontumor specimens. Relationships of C/EBP alpha expression with clinical parameters and patient survival were analyzed. RESULTS: C/EBP alpha expression was not influenced by chronic alcohol exposure, viral hepatitis, or cirrhosis, but was reduced in 60% of HCC. Reduction of C/EBP alpha was associated with advanced tumor stage (P = 0.001). Patients with markedly reduced C/EBP alpha expression had a significantly shorter survival with a hazard ratio of 5.45 (95% confidence interval, 1.93-15.40; P = 0.001). CONCLUSIONS: C/EBP alpha may be a potential prognostic marker or therapeutic target in HCC regardless of different etiology.
PURPOSE:CCAAT/enhancer binding protein alpha (C/EBP alpha) is a transcription factor and a tumor suppressor. We aimed to assess its protein expression and prognostic value in humanhepatocellular carcinoma (HCC). METHODS: We conducted a retrospective cohort study on 50 HCC patients and performed immunohistochemistry against C/EBP alpha on tumors and adjacent nontumor specimens. Relationships of C/EBP alpha expression with clinical parameters and patient survival were analyzed. RESULTS:C/EBP alpha expression was not influenced by chronic alcohol exposure, viral hepatitis, or cirrhosis, but was reduced in 60% of HCC. Reduction of C/EBP alpha was associated with advanced tumor stage (P = 0.001). Patients with markedly reduced C/EBP alpha expression had a significantly shorter survival with a hazard ratio of 5.45 (95% confidence interval, 1.93-15.40; P = 0.001). CONCLUSIONS:C/EBP alpha may be a potential prognostic marker or therapeutic target in HCC regardless of different etiology.
Authors: Balazs Halmos; Claudia S Huettner; Olivier Kocher; Katalin Ferenczi; Daniel D Karp; Daniel G Tenen Journal: Cancer Res Date: 2002-01-15 Impact factor: 12.701
Authors: Kristi L Bennett; Björn Hackanson; Laura T Smith; Carl D Morrison; James C Lang; David E Schuller; Frank Weber; Charis Eng; Christoph Plass Journal: Cancer Res Date: 2007-05-15 Impact factor: 12.701
Authors: Lan Mi; Kai Hu; Xianzi Wen; Jing Sun; Aiwen Wu; Mingliang Wang; Minhua Zheng; Lu Zang; Jiafu Ji Journal: Am J Cancer Res Date: 2018-08-01 Impact factor: 6.166
Authors: A Silvina Nacht; Roberto Ferrari; Roser Zaurin; Valentina Scabia; José Carbonell-Caballero; Francois Le Dily; Javier Quilez; Alexandra Leopoldi; Cathrin Brisken; Miguel Beato; Guillermo P Vicent Journal: EMBO J Date: 2019-08-02 Impact factor: 11.598